{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T03:22:37Z","timestamp":1778988157535,"version":"3.51.4"},"reference-count":12,"publisher":"American Association for Cancer Research (AACR)","issue":"14","funder":[{"name":"Leukemia and Lymphoma Society","award":["CDP 2331-20"],"award-info":[{"award-number":["CDP 2331-20"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,14]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>In an exploratory analysis of the phase II CAPTIVATE study, previously untreated patients with chronic lymphocytic leukemia with a higher-risk feature of immune globulin heavy chain variable (IGHV) unmutated status, del(17p), and\/or TP53 mutation had similar efficacy and safety outcomes compared with patients without a higher-risk feature when treated with fixed-duration ibrutinib and venetoclax.<\/jats:p>\n                  <jats:p>See related article by Allan et al., p. 2593<\/jats:p>","DOI":"10.1158\/1078-0432.ccr-23-0807","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T09:12:46Z","timestamp":1686215566000},"page":"2561-2562","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A CAPTIVATEing Analysis for Higher-Risk CLL"],"prefix":"10.1158","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-7874","authenticated-orcid":false,"given":"Kerry A.","family":"Rogers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"2025112507580273600_bib1","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1158\/1078-0432.CCR-22-2779","article-title":"Outcomes in patients with high-risk features after fixed-duration ibrutinib plus venetoclax: phase 2 CAPTIVATE study in first-line chronic lymphocytic leukemia","volume":"29","author":"Allan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025112507580273600_bib2","doi-asserted-by":"crossref","first-page":"EVIDoa2200006","DOI":"10.1056\/EVIDoa2200006","article-title":"Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities","volume":"1","author":"Kater","year":"2022","journal-title":"NEJM Evid"},{"key":"2025112507580273600_bib3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.clml.2019.07.004","article-title":"Long-term studies assessing outcomes of ibrutinib therapy in patients with Del(11q) chronic lymphocytic leukemia","volume":"19","author":"Kipps","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025112507580273600_bib4","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1200\/JCO.21.01181","article-title":"Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study","volume":"39","author":"Al-Sawaf","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112507580273600_bib5","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"2025112507580273600_bib6","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"2025112507580273600_bib7","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaoncol.2017.2009","article-title":"Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents: a review","volume":"4","author":"Thompson","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025112507580273600_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2022-156070","article-title":"Residual disease kinetics among patients with high-risk factors treated with first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): the glow study","volume":"140","author":"Niemann","year":"2022","journal-title":"Blood"},{"key":"2025112507580273600_bib9","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"2025112507580273600_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","article-title":"Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study","volume":"34","author":"Burger","year":"2020","journal-title":"Leukemia"},{"key":"2025112507580273600_bib11","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.3324\/haematol.2021.280376","article-title":"A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib","volume":"107","author":"Mato","year":"2022","journal-title":"Haematologica"},{"key":"2025112507580273600_bib12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-138725","article-title":"Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen","volume":"136","author":"Thompson","year":"2020","journal-title":"Blood"}],"container-title":["Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/doi\/10.1158\/1078-0432.CCR-23-0807\/3339630\/ccr-23-0807.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/29\/14\/2561\/3347504\/2561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article-pdf\/29\/14\/2561\/3347504\/2561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:58:08Z","timestamp":1764075488000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/clincancerres\/article\/29\/14\/2561\/727733\/A-CAPTIVATEing-Analysis-for-Higher-Risk-CLLA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":12,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,6,8]]},"published-print":{"date-parts":[[2023,7,14]]}},"URL":"https:\/\/doi.org\/10.1158\/1078-0432.ccr-23-0807","relation":{},"ISSN":["1078-0432","1557-3265"],"issn-type":[{"value":"1078-0432","type":"print"},{"value":"1557-3265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]}}}